Alpha 2.0
Login Register
» Journals » Transl Lung Cancer Res

Translational Lung Cancer Research

Translational Lung Cancer Research is a peer-reviewed journal dedicated to advancing the understanding and treatment of lung cancer. It focuses on bridging the gap between basic science and clinical practice by publishing high-quality research articles, reviews, and expert opinions. The journal aims to provide valuable insights into the latest advancements in lung cancer diagnosis, treatment, and prevention, ultimately improving patient outcomes and promoting translational research in this field.
Details
Abbr. Transl Lung Cancer Res
Start 2012
End Continuing
p-ISSN 2218-6751
e-ISSN 2226-4477
Country China
Language English
Metrics
h-index / Ranks: 5907 62
SJR / Ranks: 2409 1318
CiteScore / Ranks: 3928 5.90
JIF / Ranks: 2264 4.0
Recent Articles
1.
Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Chee T, Zahra C, Fong K, Yang I, Bowman R
Transl Lung Cancer Res . 2025 Feb; 14(1):124-138. PMID: 39958230
Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which...
2.
Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon mutations: a retrospective multi-center Chinese study
Xu K, Zheng X, Chen M, E M, Zhang L, Cao J, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):96-106. PMID: 39958229
Background: Uncommon epidermal growth factor receptor () gene mutant locally advanced non-small cell lung cancer (NSCLC) has been poorly documented in the literature. Our study aimed to investigate the clinical...
3.
Lobectomy plus lobe-specific lymphadenectomy as the minimum standards of curative resection for hypermetabolic clinical stage IA non-small cell lung cancer
Li R, Li Z, Li P, Chen J, Qiu B, Tan F, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):14-26. PMID: 39958228
Background: The results of three modern randomized controlled trials have proved sublobar resection as an effective procedure for early-stage non-small cell lung cancer (NSCLC) up to 2 cm. We aimed...
4.
Video-assisted mediastinocopic lymphadenectomy (VAMLA) for restaging clinical N2-3 non-small cell lung cancer (NSCLC) after neoadjuvant treatment
Reig-Oussedik N, Call S, Obiols C, Garcia-Cabo B, Sanz-Santos J, Cabanillas-Paredes L, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):58-71. PMID: 39958227
Background: Reliable mediastinal restaging after neoadjuvant treatment to rule out persistent nodal disease is essential to select patients for resection. Main endpoints of this study are: to analyse the accuracy...
5.
Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
Wespiser M, Swalduz A, Perol M
Transl Lung Cancer Res . 2025 Feb; 14(1):1-6. PMID: 39958226
No abstract available.
6.
Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors
Watanabe T, Tanahashi M, Suzuki E, Yoshii N, Kohama T, Iguchi K, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):139-149. PMID: 39958225
Background: Postoperative recurrence is a significant problem in patients with early-stage non-small cell lung cancer (NSCLC), with recurrence rates of 35% for stage IB and 50% for stage IIA. This...
7.
A novel optimization of cone beam CT frequency for lung radiation therapy based on an image-guided radiation therapy protocol and patient classification method
Zhou J, Gopal A, Zhang B, Xu H, Chen S, Yi B, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):81-95. PMID: 39958224
Background: Cone beam computed tomography (CBCT) is a standard imaging modality in the management of lung cancer with radiation therapy. The optimal frequency of CBCT imaging during a course of...
8.
Immortal time bias in survival outcomes when comparing treatment with chemotherapy versus immunochemotherapy for non-small cell lung cancer
Tsuruda K, Hektoen H, Reis Costa D, Andreassen B
Transl Lung Cancer Res . 2025 Feb; 14(1):300-302. PMID: 39958223
No abstract available.
9.
Methodological aspects of studies on survival after immunotherapy in stage IV non-small cell lung cancer
Tuminello S, Untalan M, Patel K, Taioli E
Transl Lung Cancer Res . 2025 Feb; 14(1):303-304. PMID: 39958222
No abstract available.
10.
Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report
Jiang X, Deng W, Hu Z, Cai W, Qin X, Zheng H, et al.
Transl Lung Cancer Res . 2025 Feb; 14(1):292-299. PMID: 39958221
Background: Lung cancer remains a global health challenge, with an incidence of 23% and an overall 5-year survival of only 19%, as nearly half newly diagnosed cases are at the...